您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8392 处方药 8019 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 心血管系统药物->降胆固醇
处方药:处方药
包装规格: 20毫克/片 90片/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
百时美施贵宝
生产厂家英文名:
BRISTOL MYERS SQUIBB
该药品相关信息网址1:
http://www.drugs.com/pravachol.html
该药品相关信息网址2:
http://www.medicinenet.com/pravastatin/article.htm
原产地英文商品名:
PRAVACHOL 20MG/TAB 90TABS/BOTTLE
原产地英文药品名:
PRAVASTATIN SODIUM
中文参考商品译名:
普拉固 20毫克/片 90片/瓶
中文参考药品译名:
普伐他汀钠
原产地国家批准上市年份:
1991/10/31
英文适应病症1:
With primary hypercholesterolemia
临床试验期:
完成
中文适应病症参考翻译1:
原发性高胆固醇血症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201241022135513.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文普伐他汀处方资料(仅供参考)

普伐他汀(Pravastatin)
药剂名称:
普拉固

别名: Pravachol

理化特性:
本品为3-羟基3-甲基戊二酰辅酶A还原酶(HMC-CoA还原酶)的竞争性抑制剂,HMC-CoA还原酶是胆固醇生物合成初期阶段的限速酶,本药可逆性地抑制HMC-CoA还原酶,从而抑制胆固醇的生物合成。
本药从两个方面发挥其降血脂作用:
第一是通过可逆性抑制HMC-CoA还原酶的活性,使细胞内胆固醇的量有一定程度的降低,导致细胞表面低密度脂蛋白(LDL)受体数的增加,从而加强了由受体介导的LDL的分解代谢及血液中LDL的消除;
第二是通过抑制LDL的前体-极低密度脂蛋白(VLDL)在肝脏中的合成从而抑制LDL的生成。

作用和用途: 适用于饮食限制仍不能控制的原发性高胆固醇血症(Ⅱa和Ⅱb型)

用法和用量: 成人开始剂量为10mg~20mg, 一日1次,临睡前服用,一日最高剂量40mg。

不良反应和注意:
注意事项:
1.对纯合子家族性高胆固醇血症疗效差。
2.治疗期间,应定期检查肝功能,如SGPT和SGOP增高等于或超过正常上限三倍且为持续性的,应停止治疗。
3.有肝脏疾病史或饮酒史的病人本品应慎用。
4.使用HMG-CoA还原酶抑制剂类降血脂药偶可引起CPK升高,如升高值为正常上限的10倍应停止使用。使用过程中,病人如出现不明原因的肌痛、触痛、无力、特别是伴有不适和发热者,应立即报告医生。
5.其它HMG-CoA还原酶抑制剂类降血脂药与环胞霉素,纤维酸衍生物,烟酸等同时服用,可增加肌炎和肌病的发生率,但本品与上述药物同时使用,临床试验表明并不增加肌炎和肌病的发生率。
禁忌症:
对本品过敏者,活动性肝炎或肝功能试验持续升高者,以及妊娠及哺乳期的妇女禁用。
不良反应:
不良反应可见轻度转氨酶升高,皮疹、肌痛、胸痛、恶心、呕吐、腹泻、疲乏等。
 
厂商: 施贵宝制药有限公司

Pravachol (pravastatin sodium)
Company: Bristol-Myers Squibb
Approval Status: Approved July 1996
Treatment for: cholesterol-lowering
Areas: Cardiovascular / Cardiology; Diabetes / Endocrinology; Hematology
Possible similar drugs: Pravachol

General Information
Pravachol, a cholesterol-lowering medication, has been approved to help prevent a first heart attack and reduce death from cardiovascular disease in subjects with elevated cholesterol who are at risk of a first heart attack. Pravachol's new indication also includes reducing the need for balloon angioplasty or coronary bypass surgery.

Pravachol is the only HMG CoA reductase inhibitor indicated to both reduce the risk of heart attack and slow the build-up of plaque in the coronary arteries of subjects with elevated cholesterol who have established symptoms of heart disease. Prevention of recurrent heart attack in subjects with established heart disease is known as "secondary prevention." It is estimated that there are more than four million Americans who have elevated cholesterol levels and heart disease.

Clinical Results
The new Pravachol indication is based on the Pravachol Primary Prevention Study (also known as the West of Scotland study), a landmark clinical trial demonstrating a significant reduction in the risk of a first heart attack in subjects with elevated cholesterol, but no history of heart disease. The results of this study are particularly compelling because 800,000 of the 1.25 million heart attacks that occur each year in the United States are first heart attacks. Up to one third of first heart attacks will be fatal. Prevention of first heart attack is known as "primary prevention."

The Pravachol Primary Prevention Study, evaluated the use of Pravachol in 6,595 subjects over a five-year period, demonstrated that Pravachol reduced the risk of first heart attack by 31%. Death from cardiovascular disease was reduced by 32%, and there was no increase in death from non-cardiovascular causes. In addition, the study showed that Pravachol reduced the need for coronary procedures such as balloon angioplasty and bypass surgery by 37%.

Another major finding from the Pravachol Primary Prevention Study was that Pravachol benefit, in terms of reduction in first heart attacks, begins at about six months after the initiation of therapy.

Side Effects
Pravachol therapy is well tolerated by most subjects. However, the drug should not be used by people with active liver disease or liver problems, in women who are pregnant or breast feeding, or people who are allergic to any component of the medication. The most common side effects include mild skin irritation and transient rash and gastrointestinal upset.

Additional Information
Approximately 17 million Americans with high cholesterol, but with no evidence of heart disease, are considered at risk for a first heart attack.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201241022135513.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-4-11
附件:


201241022135513.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com